DocGo Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at DocGo Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.352 $ to 1.60 $ · Last price: 0.3731 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Care Facilities
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| DocGo Inc DCGO | 0.0 | – | 5.6 | 30.1 | – | -47.7 | -74.8 |
| HCA Healthcare, Inc. HCA | 95.2 | 15.2 | 9.0 | 42.6 | 15.0 | 7.1 | 8.2 |
| Tenet Healthcare Corporation THC | 22.6 | 14.0 | 5.8 | 41.7 | 17.9 | 3.1 | 42.8 |
| Encompass Health Corp EHC | 12.2 | 21.3 | 9.8 | 43.9 | 19.0 | 10.5 | -0.2 |
| DaVita HealthCare Partners Inc DVA | 11.7 | 18.1 | 8.9 | 32.4 | 13.9 | 6.5 | 43.0 |
| Universal Health Services Inc UHS | 10.9 | 7.9 | 5.5 | 44.6 | 11.2 | 9.7 | -3.1 |
| The Ensign Group Inc ENSG | 10.2 | 29.2 | 19.3 | 16.6 | 9.0 | 18.7 | 5.6 |
| Chemed Corp CHE | 6.7 | 29.8 | 15.7 | 33.1 | 12.9 | 4.1 | 11.2 |
| PACS Group, Inc. PACS | 6.5 | – | 20.3 | 17.3 | 8.5 | 29.3 | 274.9 |
| Median of companies shown | 10.9 | 18.1 | 9.0 | 33.1 | 13.4 | 7.1 | 8.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 48 | -21 | -20 | -0.20 | -14 | 68 | 101 |
| 2020 | 94 | -15 | -14 | -0.14 | -11 | 55 | 100 |
| 2021 | 319 | 15 | 24 | 0.25 | -2 | 227 | 310 |
| 2022 | 441 | 22 | 35 | 0.34 | 29 | 273 | 393 |
| 2023 | 624 | 15 | 7 | 0.06 | -64 | 301 | 490 |
| 2024 | 617 | 29 | 20 | 0.18 | 70 | 321 | 456 |
| 2025 | 322 | -89 | -182 | -1.84 | 34 | 144 | 217 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.03 | -144.70 | 121 | -39.40 | -2.70 | 13 | 12 |
| 2025: Q1 | -0.09 | -189.50 | 96 | -50.00 | -9.80 | 10 | 8 |
| 2025: Q2 | -0.11 | -285.80 | 80 | -51.20 | -13.90 | 34 | 32 |
| 2025: Q3 | -0.28 | -660.00 | 71 | -48.90 | -39.20 | 2 | 0 |
| 2025: Q4 | -1.37 | – | 75 | -38.00 | -178.90 | -11 | -13 |
| 2026: Q1 | -0.15 | – | 76 | -21.30 | -19.50 | -4,657,807 | -5,088,117 |
| 2026: Q2 | -0.16 | -45.50 | 73 | -8.70 | -21.50 | -9 | -10 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Downward Momentum
- Going Concern (Distress Proxy)
- Near 52-Week Low
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.79 | -0.92 – -0.67 | 307 | 55.9% | 2 |
| 12/31/2027 | 0.14 | -0.04 – 0.32 | 326 | 117.9% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -9.9%
- More than 10% revenue growth is expected for the coming year 6.7%
- Share count grows by less than 3% a year -1.3%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -39.4%
- Gross margin at 40% or higher and without meaningful erosion 30.7%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 22 m net cash
- Operating cash flow covers the profits of the last three years 196 m
- Return on capital at 15% or higher, or up versus two years ago -59.6%
- Insiders hold at least 10% or are net buyers 3.1%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 37.2%
- Exp. sales growth 3Y > 5% 0.6%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 0.6%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 4
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -126.7%
- ROCE > 15% -59.6%
- Expected return > 10% 76.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
DocGo Inc. ist ein Unternehmen für mobile Gesundheitsdienste in den USA und dem Vereinigten Königreich.
- Employees
- 2,537
- Headquarters
- New York, NY
- Address
- 685 Third Avenue, 10017 New York, United States
- Phone
- 844 443 6246
- Website
- docgo.com
- IPO Date
- 11/05/2021
- ISIN
- US2560861096
Management
| Name | Title | Birth Year |
|---|---|---|
| Lee Bienstock | CEO & Director | 1985 |
| Norman Rosenberg | Treasurer & CFO | 1970 |
| Ely D. Tendler J.D. | General Counsel, Secretary & Director | 1968 |
| Eiwe Lingefors | Chief Information Officer | – |
| Mike Cole | Vice President of Investor Relations | – |
| Stephen Sugrue | Chief Compliance Officer | 1973 |
| Rosemarie Milano | Vice President of Human Resources | – |
| James Powell M.D. | CEO of Clinical Practice Group & Member of Medical Advisory Board | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.